bpc-157 clinical evidence human randomized trial BPC-157: What the Science Actually Says Why would a patient trust

Please discuss goals and expectations with our medical provider

Henrik Toft Srensen: nothing to disclose Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.03 - EPIDEMIOLOGY & RISK FACTORS P1018 - ESOC25-929 ASSESSING STROKE RISK DISPARITIES: A COMPREHENSIVE ANALYSIS OF LIFESTYLE AND VASCULAR RISK FACTORS IN TRANSGENDER STROKE SURVIVORS Roham Sarmadian 1 , Ajith Vemuri 1 , Vida Abedi 1 , Ramin Zand 1 1 The Pennsylvania State University, Hershey, United States Background and Aims: Transgender individuals represent a vulnerable population with unique healthcare needs

Plan for 4-8 weeks minimum

| BPC-157 (Body Protection Compound 157) is a synthetic peptide derived from a protein fragment found in human gastric juice, studied for potential roles in tissue repair, inflammation regulation, and gastrointestinal protection

[3] Specifications Sequence: Ac-SDKP Molecular Formula: C20H33N5O9 Molecular Weight: 487.5 g/mol Size: 60 Capsules | Each capsule contains 500mcg BPC-157 Arginate Salt & 500mcgs Thymosin Beta 4 Potential Benefits of BPC-157 Thymosin Beta-4 Capsules Sweden Nervous System Thymosin Beta 4 promotes central and peripheral nervous system tissue development in injured rodents